Oral antidiabetic drugs in treatment of type 1 diabetes mellitus

Česká verzia

Authors: Ludmila Brunerová ¹; Jan Brož ²
Authors place of work: Diabetologické centrum II. interní kliniky 3. LF UK a FN Královské Vinohrady, Praha ¹; Interní klinika 2. LF UK a FN v Motole, Praha ²
Published in the journal: Vnitř Lék 2016; 62(12): 998-1003
Category: Reviews

Summary

Review article summarizes current knowledge of the use of oral antidiabetics (approved for treatment of type 2 diabetes) in type 1 diabetic patients. Following drugs were tested: metformin, gliptines, analogues of GLP-1, glitazones, inhibitors of α-glukozidase and gliflozines. The latter seem to be the most perspective ones, however, more studies are warranted for definitive confirmation of their efficacy and safety. Current evidence-based results did not clearly show efficacy and safety of oral antidiabetics as adjuvant treatment in type 1 diabetic patients and thus, they still represent off-label treatment in this type of diabetes.

Key words:
oral antidiabetics – type 1 diabetes mellitus

Zdroje

1. Proks P, Reimann F, Green N et al. Sulfonylurea Stimulation of Insulin Secretion. Diabetes 2002; 51(suppl 3): S368-S376.

2. Rena G, Pearson ER, Sakamoto K. Molecular mechanism of action of metformin: old or new insights? Diabetologia 2013; 56(9): 1898–1906.

3. Hauner H. The mode of action of thiazolidinediones. Diabetes Metab Res Rev 2002; 18(Suppl 2): S10-S15.

4. Haluzík M. Praktická léčba diabetu. 2. ed. Mladá fronta: Praha 2013. ISBN 978–80–204–2880–6.

5. Bailey CJ, Day C. SGLT2 Inhibitors: Glucuretic Treatment for Type 2 Diabetes. Br J of Diabetes Vasc Dis 2010; 10(4): 193–199. Dostupné z DOI: <http://dx.doi.org/10.1177/1474651410377832>.

6. Rodbard D. Continuous Glucose Monitoring: A Review of Successes, Challenges, and Opportunities. Diabetes Technol Ther 2016; 18(Suppl 2): S23-S213. Dostupné z DOI: <http://dx.doi.org/10.1089/dia.2015.0417>.

7. Heinemann L, Benesch C, DeVries JH. [AP@home Consortium]. The Artificial Pancreas Is Now at Home. J Diabetes Sci Technol 2016; 10(4):950–958. Dostupné z DOI: <http://dx.doi.org/10.1177/1932296816632002.

8. Nathan DM. Diabetes: Advances in Diagnosis and Treatment. JAMA 2015; 314(10): 1052–1062. Dostupné z DOI:

9. Greeley SA, Naylor RN, Philipson LH et al. Neonatal diabetes: an expanding list of genes allows for improved diagnosis and treatment. Curr Diab Rep 201; 11(6): 519–532. Dostupné z DOI: <http://dx.doi.org/10.1007/s11892–011–0234–7.

10. Anık A, Çatlı G, Abacı A et al. Maturity-onset diabetes of the young (MODY): an update. J Pediatr Endocrinol Metab 2015; 28(3–4): 251–263. Dostupné z DOI:

11. Cleland SJ, Fisher BM, Colhoun HM et al. Insulin resistance in type 1 diabetes: what is ‘double diabetes’ and what are the risks? Diabetologia 2013; 56(7): 1462–1470. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125–013–2904–2>.

12. Polsky S, Ellis SL. Obesity, insulin resistance, and type 1 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 2015; 22(4): 277–282. Dostupné z DOI: <http://dx.doi.org/10.1097/MED.0000000000000170>.

13. Munir KM, Davis SN. The treatment of type 1 diabetes mellitus with agents approved for type 2 diabetes mellitus. Expert Opin Pharmacother 2015; 16(15): 2331–2341. Dostupné z DOI: <http://dx.doi.org/10.1517/14656566.2015.1084502>.

14. Viollet B, Guigas B, Sanz Garcia N et al. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) 2012; 122(6): 253–270. Dostupné z DOI: <http://dx.doi.org/10.1042/CS20110386>.

15. Libman IM, Miller KM, DiMeglio LA. T1D Exchange Clinic Network Metformin RCT Study Group. Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial. JAMA 2015; 314(21): 2241–2250. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2015.16174>.

16. Konrad K, Datz N, Engelsberger I et al. [German/Austrian DPV Initiative]. Current use of metformin in addition to insulin in pediatric patients with type 1 diabetes mellitus: an analysis based on a large diabetes registry in Germany and Austria. Pediatr Diabetes 2015; 16(7): 529–537. Dostupné z DOI: <http://dx.doi.org/10.1111/pedi.12203>.

17. Liu C, Wu D, Zheng X et al. Efficacy and safety of metformin for patients with type 1 diabetes mellitus: a meta-analysis. Diabetes Technol Ther 2015; 17(2): 142–148. Dostupné z DOI: <http://dx.doi.org/10.1089/dia.2014.0190>.

18. Dupre J. Glycaemic effects of incretins in type 1 diabetes mellitus: A concise review, with emphasis on studies in humans. Regul Pept 2005; 128(2): 149–157. Erratum in Regul Pept 2006; 134(1): 67–68.

19. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132(6): 2131–2157.

20. Ellis SL, Moser EG, Snell-Bergeon JK et al. Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial. Diabet Med 2011; 28(10): 1176–1181. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1464–5491.2011.03331.x>.

21. Kutoh E. Sitagliptin is effective and safe as add-on to insulin in patients with absolute insulin deficiency: a case series. J Med Case Rep 2011; 5: 117. Dostupné z DOI: http://dx.doi.org/<10.1186/1752–1947–5-117>.

22. George PS, McCrimmon RJ. Saxagliptin co-therapy in C-peptide-negative Type 1 diabetes does not improve counter-regulatory responses to hypoglycaemia. Diabet Med 2016; 33(9): 1283–1290. Dostupné z DOI: <http://dx.doi.org/10.1111/dme.13046>.

23. Farngren J, Persson M, Schweizer A et al. Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes. J Clin Endocrinol Metab 2012; 97(10): 3799–3806. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2012–2332>.

24. Schopman JE, Hoekstra JB, Frier BM et al. Effects of sitagliptin on counter-regulatory and incretin hormones during acute hypoglycaemia in patients with type 1 diabetes: a randomized double-blind placebo-controlled crossover study. Diabetes Obes Metab 2015; 17(6): 546–553. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.12453>.

25. Unger J. Rationale use of GLP-1 receptor agonists in patients with type 1 diabetes. Curr Diab Rep 2013; 13(5): 663–668. Dostupné z DOI: <http://dx.doi.org/10.1007/s11892–013–0404.

26. Dejgaard TF, Frandsen CS, Hansen TS et al. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2016; 4(3): 221–232. Dostupné z DOI:

27. Frandsen CS, Dejgaard TF, Holst JJ et al. Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study. Diabetes Care 2015; 38(12): 2250–2257. Dostupné z DOI: <http://dx.doi.org/10.2337/dc15–1037>.

28. Raman VS, Mason KJ, Rodriguez LM et al. The role of adjunctive exenatide therapy in pediatric type 1 diabetes. Diabetes Care 2010; 33(6): 1294–1296. Dostupné z DOI: <http://dx.doi.org/10.2337/dc09–1959>.

29. Traina AN, Lull ME, Hui AC et al. Once-weekly exenatide as adjunct treatment of type 1 diabetes mellitus in patients receiving continuous subcutaneous insulin infusion therapy. Can J Diabetes 2014; 38(4): 269–272. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jcjd.2013.10.006>.

30. Sarkar G, Alattar M, Brown RJ et al. Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes. Diabetes Care 2014; 37(3): 666–670. Dostupné z DOI: <http://dx.doi.org/10.2337/dc13–1473>.

31. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351(11): 1106–1118.

32. Bhat R, Bhansali A, Bhadada S et al. Effect of pioglitazone therapy in lean type 1 diabetes mellitus. Diabetes Res Clin Pract 2007; 78(3): 349–354.

33. Tafuri KS, Godil MA, Lane AH et al. Effect of pioglitazone on the course of new-onset type 1 diabetes mellitus. J Clin Res Pediatr Endocrinol 2013; 5(4): 236–239. Dostupné z DOI: <http://dx.doi.org/10.4274/Jcrpe.981>.

34. Yang Z, Zhou Z, Li X et al. Rosiglitazone preserves islet beta-cell function of adult-onset latent autoimmune diabetes in 3 years follow-up study. Diabetes Res Clin Pract 2009; 83(1): 54–60. Dostupné z DOI: <http://dx.doi.org/10.1016/j.diabres.2008.09.044>.

35. Stone ML, Walker JL, Chisholm D et al. The addition of rosiglitazone to insulin in adolescents with type 1 diabetes and poor glycaemic control: a randomized-controlled trial. Pediatr Diabetes 2008; 9(4 Pt 1): 326–334. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1399–5448.2008.00383.x>.

36. Kubo S, Watada H, Kawamori R. Combination therapy of miglitol and insulin in type 1 diabetes mellitus patients. J Diabetes Investig 2010; 1(1–2): 60–65. Dostupné z DOI: <http://dx.doi.org/10.1111/j.2040–1124.2010.00011.x>.

37. Nagai E, Katsuno T, Miyagawa J et al. Effects of miglitol in combination with intensive insulin therapy on blood glucose control with special reference to incretin responses in type 1 diabetes mellitus. Endocr J 2011; 58(10): 869–877.

38. Riccardi G, Giacco R, Parillo M et al. Efficacy and safety of acarbose in the treatment of Type 1 diabetes mellitus: a placebo-controlled, double-blind, multicentre study. Diabet Med 1999; 16(3): 228–232.

39. Rabasa-Lhoret R, Burelle Y, Ducros F et al. Use of an alpha-glucosidase inhibitor to maintain glucose homoeostasis during postprandial exercise in intensively treated Type 1 diabetic subjects. Diabet Med 2001; 18(9): 739–744.

40. Henry RR, Thakkar P, Tong C et al. Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes. Diabetes Care 2015; 38(12): 2258–2265.Dostupné z DOI: <http://dx.doi.org/10.2337/dc15–1730>.

41. Henry RR, Rosenstock J, Edelman S et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care 2015; 38(3): 412–419. Dostupné z DOI: <http://dx.doi.org/10.2337/dc13–2955>.

42. Pieber TR, Famulla S, Eilbracht J et al. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1). Diabetes Obes Metab 2015; 17(10): 928–935. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.12494>.